Background: The aim of this study was to assess the efficacy of a fixed nitrous oxide/oxygen mixture for the management of breakthrough cancer pain. Methods/design: A double-blind, placebo-controlled, randomized clinical trial was undertaken in the Medical ward of Tumor Hospital of General Hospital of Ningxia Medical University. 240 cancer patients with breakthrough pain were recruited and randomly received a standard pain treatment (morphine sulphate immediate release) plus a preprepared nitrous oxide/oxygen mixture, or the standard pain treatment plus oxygen. The primary endpoint measure was the numerical rating scale (NRS) score measured at baseline, 5 and 15 min after the beginning of treatment, and at 5 min post treatment. Result: In all, analysis of pain score (NRS) at 5 min after the beginning of treatment shown a significant decrease in nitrous oxide/oxygen mixture treated patients with 2.8 AE 1.3 versus 5.5 AE 1.2 in controls (p < 0.01). At 15 min during the intervention, the mean pain score for nitrous oxide/oxygen was 2.0 AE 1.1 compared with 5.6 AE 1.3 for oxygen (p < 0.01). Conclusion: This study shows that self-administered nitrous oxide/ oxygen mixture was effective in reducing moderate to severe breakthrough pain among patients with cancer. Significance: The management of breakthrough cancer pain is always a challenge due to its temporal characteristics of rapid onset, moderate to severe in intensity, short duration (median 30-60 min). Our study find that self-administered nitrous oxide/oxygen mixture was effective in reducing moderate to severe breakthrough cancer pain.
Introduction
Cancer has been considered the leading cause of non-accidental death in China since 2010 (Chen et al., 2016) . This disease induces pain, which has emerged as its concerning and common symptom (Allen et al., 2016) . For instance breakthrough pain (BTP) in cancer is defined as a transient exacerbation of pain, which is greater than moderate intensity, and it occurs either spontaneously or in relation to a specific and predictable or unpredictable trigger despite the occurrence of well-controlled background pain (Davies et al., 2009) . BTP is highly prevalent in a population of patients with chronic cancer pain (30-89%; Katz et al., 2017) . BTP also varies among individuals and within a given individual in terms of its clinical characteristics (Zeppetella, 2011; Caraceni et al., 2013) . For example BTP exhibits fast onset (median interval of 3 min to peak pain), short duration (median, 30-60 min), moderate-to-severe intensity and self-limitation (median number of four times or episodes per day ranging from 1 to >10) (Davies, 2011; Caraceni et al., 2013; Daeninck et al., 2016) .
Breakthrough pain has yet to be optimally treated (Margarit et al., 2012) and has consequently caused considerable psychological distress, such as increased depression and anxiety levels, physical and economic burdens and deteriorated quality of life (Burton and Zeppetella, 2011; Webber et al., 2011; B€ orjeson et al., 2012; Hjermstad et al., 2016) .
Breakthrough pain management must be individualized because of its heterogeneous condition (Davies, 2011) . In traditional BTP management approaches, morphine sulphate immediate release with rescue doses is the first-line drug option to manage BTP episodes. However, the pharmacokinetic profile of this agent does not correlate with the optimal speed of the onset nature of a BTP episode (Zeppetella, 2011; Vellucci et al., 2015; Daeninck et al., 2016) . Various transmucosal fentanyl formulations, including fentanyl buccal soluble film, fentanyl buccal tablet, fentanyl pectin nasal spray, intranasal fentanyl spray, oral transmucosal fentanyl citrate (OTFC) and sublingual fentanyl (Potter, 2006; Zeppetella, 2008; Zeppetella and Davies, 2013; Zeppetella et al., 2014) , have been used to alleviate BTP. These formulations stimulate action within 10-15 min after administration, but these formulations should be titrated to an effective and tolerable dose for each patient, and patients have to undergo a maximum of 26 days of the dose-titration phase (Liu et al., 2017) .
A fixed inhaled nitrous oxide/oxygen mixture, available in pre-prepared cylinders, is an analgesic employed in several areas of pain management (Huang and Johnson, 2016) . It causes analgesia without the loss of consciousness, and the absorbed gas is readily cleared from the blood stream via the lungs. This drug exhibits low blood/gas solubility that allows rapid onset (1-2 min) and clearance (35-45 s; Kariman et al., 2011) . This mixture also provides rapid relief from pain and anxiety, but this relief is quickly reversed after discontinuation (Gholam et al., 2015) . The safety of nitrous oxide/oxygen mixture for pain management has been demonstrated, and self-administered inhaled nitrous oxide/ oxygen mixture helps patients become independent from additional medical staff or facilities required to monitor them during the whole process.
We tested the hypothesis that the pain scores of patients suffering from cancer and taking nitrous oxide/oxygen mixture after BTP episodes are lower than those of patients receiving oxygen.
Methods

Design
A double-blind (patient and outcome assessor), placebo-controlled, randomized clinical trial was undertaken in the medical ward of the Tumor Hospital of the General Hospital of Ningxia Medical University as described in a published study protocol (Liu et al., 2017) .
Approvals and governance
This study was approved by the Ningxia Medical University Ethics Committee (2016-143) , and the trial was registered in China Registry of Clinical Trials (ChiCTR-INC-16008075). Patients provided written informed consent for participation in accordance with national regulations.
Patients
Patients suffering from cancer, experiencing BTP, aged 18 years or older and showing an ability to read clinical trial literature and give consent were recruited between July 2016 and February 2017. Patients were excluded if they had a contraindication for nitrous oxide use or if their Karnofsky Performance Status Scale score was equal or <20. The inclusion and exclusion criteria are shown in Table 1 . Davies' Adapted Diagnostic Algorithm (Davies et al., 2009 ) was used to screen patients with cancer for the presence of BTP. After the initial assessment was completed, eligible patients with BTP provided their informed consent.
Randomization and blinding
Each patient was assigned to treatment groups with a computer-generated randomization list by an independent statistician. A total of 240 participants were randomized into three treatment groups (A, B, C; n = 180) and one control group (D; n = 60) at a 3:1 ratio. This list contained 60 numbers (between 1 and 240) allocated to oxygen group and 180 allocated to nitrous oxide/oxygen group. The randomization list was kept and sealed by a project manager, who was responsible for the gas distribution of each newly enrolled patient. Participants and outcome assessors were blinded to treatment at all times throughout the whole trial. The outcome assessor was prevented from discussing information regarding the trial. The project manager was not involved in patient recruitment, consent, randomization or data collection.
Interventions
Throughout the study, the patients continued their fixed scheduled opioid regimens. All BTP participants received morphine sulphate immediate release at 10-20% of the total daily opioid dosage as standard pain treatment for each BTP episode. They were then planned to receive pre-prepared nitrous oxide/ oxygen mixture or oxygen for each BTP event. The order of administration was computer generated. A fixed concentration of nitrous oxide/oxygen mixture was self-administered by each patient using a specially designed mask with a one-way valve (Liu et al., 2017) . In this method, the patients held their own mask, and the risk of overdose was low because the patients' level of consciousness influenced their ability to maintain gas flow (Kariman et al., 2011 ).
Outcome measures
In addition to patient's demographic data, including age, gender nationality, height and weight, cancer diagnosis and baseline BTP intensity were determined at the baseline from a computer-based patient record. The primary endpoint measure was the numerical rating scale (NRS) (Muley et al., 2016) score measured at baseline (T0), 5 min (T1) and 15 min (T2) after the beginning of treatment and at 5 min (T3) post treatment. The NRS is a self-rating tool with a scale from 0 to 10 (0 = no pain, 10 = worst pain), and this tool demonstrates good reliability, validity and responsiveness in cancer pain trials (Ripamonti and Brunelli, 2009) . A range of secondary measures was also measured in terms of treatment safety at T0, T1, T2 and T3. Patients' and healthcare professionals' satisfaction with this treatment was assessed by a five-point satisfaction scale (5, very satisfied; 4, satisfied; 3, uncertain; 2, dissatisfied; 1, very dissatisfied). The observed adverse effects of nitrous oxide/oxygen and oxygen were recorded during the whole intervention.
Sample size
On the basis of our preliminary study, we assessed BTP with nitrous oxide/oxygen mixture or oxygen in 20 consecutive patients with cancer and found that 90% of patients receiving nitrous oxide/oxygen experienced at least 30% relief in pain intensity (cut off point) at 15 min compared to 10% of patients receiving oxygen. A total of 12 breakthrough cancer pain patients were sufficient to demonstrate its efficiency, with type I error of 0.05 and a power of 90%. We increased this figure to a total of 240 subjects to meet the Chinese Food and Drug Administration standard for feasibility and the safety of nursing staff in implementing this analgesic.
Statistical analysis
Statistical analysis was performed following the intention-to-treat (ITT) principle, with SPSS version 22.0 (SPSS Inc., IBM Company, Chicago, IL, USA). Descriptive statistics were used to describe the baseline characteristics of the participants. The baseline characteristics were presented as medians (interquartile ranges, IQR), means (standard deviations, SD) or proportions (exact binomial 95% confidence intervals, 95% CI). Repeated measures analysis of variance (ANOVA) was used to compare the difference between groups. Mann-Whitney test (non-normal distribution parameters) was used for the satisfaction of health professionals and patients. The two-sided statistical significance level was given by 0.05. and February 18, 2017 were screened for eligibility by the research team. Of these patients, 26 eligible patients declined to give consent for participation in this study, 101 patients did not satisfy the inclusion or exclusion criteria and 11 patients were excluded for other reasons. The 240 remaining patients were randomly assigned to treatment groups (Fig. 1) . All the participants finished the study. Patients' demographic and baseline characteristics are presented in Table 2 , and the following characteristics were similar in the two groups: age (median = 54 years; IQR = 47-63 years), gender (158 males, 66%), initial pain scores (median = 6.6, IQR = 6-7) or other characteristics. The most common cancer types were gastric, lymph, colon and rectum cancers. In episodes treated with nitrous oxide/oxygen mixture, pain intensity decreased from 6.6 AE 1.2 to 2.8 AE 1.2, 2.0 AE 1.1 and 0.7 AE 0.7 at T1, T2 and T3, respectively. In episodes treated with oxygen, pain intensity decreased from 6.6 AE 1.3 to 5.5 AE 1.2, 5.6 AE 1.3 and 0.6 AE 0.7 at T1, T2 and T3, respectively (Table 3 ). The pain score (NRS) at 5 min after the beginning of treatment significantly decreased in patients treated with nitrous oxide/oxygen mixture (2.8 AE 1.3 vs. 5.5 AE 1.2 in controls; p < 0.01). At 15 min during the intervention, the mean pain scores of the patients receiving nitrous oxide/oxygen and oxygen were 2.0 AE 1.1 and 5.6 AE 1.3, respectively (p < 0.01; Fig. 2 ). Improvement was greater in both groups at T3, but the differences between the groups did not reach statistical significance.
The analysis of the other characteristics at T2 revealed that heart rate, diastolic pressure and systolic pressure were not different between the two groups. The mean oxygen saturation levels of the patients receiving nitrous oxide/oxygen and oxygen were (98.5 AE 0.9) and (99.1 AE 0.7) percent (p < 0.01), respectively ( Table 4 ). The analysis of the secondary outcomes indicated that the satisfaction of the patients receiving nitrous oxide/oxygen mixture significantly increased compared with that of the patients taking oxygen (Z = À11.96, p < 0.01). The satisfaction of health professionals also increased.
No serious adverse events related to nitrous oxide/ oxygen mixture were reported. The adverse effects of the treatment on the two groups are presented in Table 5 . For the patients with adverse effects, no treatment was required. All adverse effects disappeared 4 h after the procedure was completed.
Discussion
The pathogenesis of BTP onset is probably heterogeneous, and a possible mechanism underlying BTP onset can be associated with a transient increase in the involvement of primary (or secondary) neoplastic lesion-dependent factors or after the occurrence of additional algogenic stimuli originating from neoplastic tissues. A neoplastic mass may induce transient stimulation via nearby sensitive structures, such as nerves under compression. A new stimulus, such as secondary movement or swallowing, which is not necessarily painful under normal conditions, can exceed the nociceptor threshold and produce an intense pain through allodynia from non-painful stimuli and hyperalgesia from painful stimuli. This type of pain is clinically characterized by its ability to be confined in its originating tissue. Pain also occurs in other sites, such as the innervation area of nerve structures involved, when the neoplasm affects adjacent tissues. Pain duration is generally linked to the duration of a stimulus, such as movement, posture or changes in posture and defecation (Zucco et al., 2014) .
Nitrous oxide/oxygen mixture, which is generally an odourless gas, has been widely used in several areas, including dentistry, operating room, emergency department, venipuncture and fracture reduction, because of its pain relief properties. The mechanism of the action of nitrous oxide has been reviewed (Maze and Fujinaga, 2000; Emmanouil and Quock, 2007) . Nitrous oxide provides analgesic effects through the non-competitive inhibition of excitatory NMDA subtype glutamate receptors.
Nitrous oxide also stimulates endogenous opioid peptide release and subsequently activates opioid receptors, aminobutylic acid type A (GABA) and noradrenergic pathways (Meier et al., 2015) .
To our knowledge, this study was the first to perform a randomized, placebo-controlled and doubleblind trial of pre-prepared nitrous oxide/oxygen mixture for patients suffering from cancer and experiencing BTP episodes in a tumour medical ward. In our study, this fixed pre-prepared nitrous oxide/oxygen mixture effectively decreased cancerinduced BTP when the standard treatment with morphine sulphate immediate release at 10-20% of the total daily opioid dosage patch was used. In addition, the number of the adverse effects of nitrous oxide/oxygen was low and no severe complications were observed. The satisfaction of medical workers and patients regarding this analgesic treatment was higher than that of the control group. BTP episodes vary among individuals and within individuals. Thus, managing BTP remains challenging because of its heterogeneous condition despite the wide use of opioids recommended by WHO. Morphine sulphate immediate release has been widely used as 'rescue medication' to control BTP, and this treatment is still administered to patients in northwest China. However, BTP exhibits rapid onset and moderate-to-severe intensity. The time-action profile of the oral administration of morphine demonstrated that more than 30 min is needed to become effective, and the peak effect occurred at 40-60 min. Therefore, patients have to endure pain for about 30 min. In this case, the pain scores of patients suffering from cancer and receiving nitrous oxide/oxygen mixture plus morphine sulphate immediate release might be lower than that of patients experiencing cancer and taking oxygen plus morphine sulphate immediate release in the first 30 min. We also found that the pain scores of patients administered with nitrous oxide/oxygen mixture were lower than those of patients treated with oxygen at 5 and 15 min. The transmucosal formulation of fentanyl has been widely investigated to control BTP in patients with cancer because of its fast and efficient analgesic action suitable for BTP management. Studies on sublingual fentanyl tablet (Coluzzi et al., 2001) , oral transmucosal fentanyl citrate lozenges (Coluzzi et al., 2001; Nalamachu et al., 2014) and fentanyl sublingual spray (Rauck et al., 2012) have revealed that the effective dose of the transmucosal fentanyl preparation used to manage BTP is not correlated with the effective total daily opioid dosage. In other words, the dosage of breakthrough medication should be routinely individualized with a titration strategy to reach an optimal dose. A network metaanalysis has also assessed the clinical value of BTP medications and suggested that only intranasal fentanyl spray provided clinically meaningful pain relief at 15 min (Zeppetella et al., 2014) . In this study, nitrous oxide/oxygen mixture was effective and safe for almost all BTP episodes and capable of providing rapid analgesic effects.
Other studies on nitrous oxide/oxygen mixture have demonstrated a similar analgesic effect. During burn wound dressing (Li et al., 2013) , nitrous oxide/ oxygen mixture significantly reduces burn dressing pain and burn-pain-related anxiety. During laceration repair (Bar-Meir et al., 2006; Lee et al., 2012) , nitrous oxide is a safe and effective analgesia to alleviate infiltration and suturing pain and to control primary wound closure pain. A randomized, doubleblind, placebo-controlled study has evaluated the efficacy of nitrous oxide/oxygen for the treatment of adult patients with moderate traumatic acute pain (Bar-Meir et al., 2006) . Nitrous oxide/oxygen has also been applied in a cancer setting for refractory pain treatment. Using nitrous oxide/oxygen for BTP management has been reported in three small case studies, but a mixture of varying results have been obtained. The use of self-administered nitrous oxide/ oxygen is effective as BTP treatment for four of ten inpatients with unsatisfactory response to maximally tolerated rescue opioids, and these patients experienced more than 50% of pain relief (Enting et al., 2002) . Nitrous oxide is a useful supplement to treat poorly controlled cancer pain in patients (Keating and Kundrat, 1996) . Environmental exposure to medical workers and caregivers is also safe and minimal. However, these two studies did not use placebo and were not controlled. In a double-blind crossover case series study, self-administered inhaled nitrous oxide is beneficial to five of seven patients during the incident pain episodes (Parlow et al., 2005) . Associating specific adverse events with nitrous oxide/oxygen or morphine sulphate immediate release was difficult because the patients with cancer in the study received concomitant fixed scheduled opioid regimen and morphine sulphate immediate release to control BTP episodes. The adverse effects could not be definitively attributed to nitrous oxide/ oxygen mixture. In addition, the two groups did not significantly differ in terms of the incidence of total adverse events. These events were generally mild to moderate in intensity and all fully reversible without other complications.
Nitrous oxide causes few adverse effects (Li et al., 2013; Huang and Johnson, 2016) . In one study, oral transmucosal fentanyl citrate is compared with morphine sulphate immediate release to control BTP in patients suffering from cancer and receiving a fixed scheduled opioid regimen. The most common opioid-related adverse effects on days that opioids are taken are somnolence (15%), nausea (13%) and dizziness (7%) (Coluzzi et al., 2001 ). Rauck et al. (Rauck et al., 2009 ) evaluated the efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of BTP in cancer and showed that 73.3% of patients experienced at least one treatment-emergent adverse effect during the study. The results shows that 73.3% of patients experienced at least one treatment-emergent adverse effect during the study, 25.2% of whom experienced at least one adverse effect of severe intensity. 31.3% of patients experienced a treatment-emergent adverse reaction. The most common study drug reactions were nausea (12.2%), vomiting (5.3%) and somnolence (4.6%). In a multicentre, randomized, doubleblinded and placebo-controlled trial of OTFC for cancer-related BTP (Farrar et al., 1998) , the most frequent opioid-related adverse events are dizziness (17%), nausea (14%), somnolence (8%), constipation (5%), asthenia (5%), confusion (4%), vomiting (3%) and pruritus (3%). Portenoy et al. (Portenoy et al., 2006 )designed a study to evaluate the efficacy, safety and tolerability of fentanyl buccal tablet in opioid-treated patients with chronic pain associated with cancer observed that the most commonly reported adverse events are those associated with opioid use: nausea (22%), vomiting (11%), dizziness (22%), headache (15%), constipation (11%) and somnolence (10%). The adverse effects found in our study could be related to the fixed dose of morphine sulphate immediate release taken by the patients.
Conclusion
Compared with placebo, self-administered nitrous oxide/oxygen mixture can be applied to reduce moderate-to-severe BTP among patients with cancer. Patients who received nitrous oxide/oxygen mixture treatment during BTP episodes and medical workers experienced great satisfaction. Nitrous oxide/oxygen can be used widely in low-resource settings because it exhibits analgesic properties and causes a low incidence of side effects. 
